| Company Name: | Aastrom Biosciences, Inc. | | Ticker Symbol: | ASTM | | | WWW Address: | www.aastrom.com |
| CEO: | Dominick Colangelo | | No. of Employees: | 77 |
| Common Issue Type: | CS | | Business Description: | Aastrom Biosciences, Inc., is a regenerative medicine company that focuses on the development of innovative cell therapies to repair or regenerate damaged or diseased tissues.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 0.5735 |  -0.0115 | 0.55 | 0.6997 | 0.59 | 0.59 | 0.57 | 145888 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 26.2 | 45.7 | 0.03 | -0.81 | 0.00 | 0.0 | 0.0 | 2.35 - 0.52 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 0.57 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 26.2 | mil |
| Latest Shares Outstanding | 45.7 | mil |
| Earnings pS (EPS) | -0.81 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 273 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 43.2 | mil |
| Float as % of Shares Outstanding | 96.7 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 28,225.90 | % |
| Research & Devlopment (R&D) as % of Revenue | 91,729.60 | % |
| Gross Profit Margin | 77.8 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.0 | % |
| Return on Assets (ROA) | -330.9 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | 95.8 | % |
| Current Ratio | 2.2 | |
| Leverage Ratio (Assets/Equity) | 0.0 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 0.11 | $ |
| Cash pS | 0.20 | $ |
| Book-Value pS | 0.00 | $ |
| Tangible Book-Value pS | -0.80 | $ |
| Cash Flow pS | -0.86 | $ |
| Free Cash Flow pS | -0.66 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.00 | |
| Price/Tangible Book Ratio | -0.72 | |
| Price/Cash Flow | -0.7 | |
| Price/Free Cash Flow | -0.9 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.6 | 101 | 2,332 | 2,464 |
| 4 Weeks | 0.67 | 0.52 | 0.69 | -16.9 | 79 | 3,494 | 59,398 |
| 13 Weeks | 1.34 | 0.52 | 1.20 | -52.2 | 43 | 4,657 | 284,076 |
| 26 Weeks | 1.49 | 0.52 | 1.18 | -51.4 | 41 | 3,825 | 466,591 |
| 52 Weeks | 2.35 | 0.52 | 2.05 | -72.0 | 22 | 2,987 | 734,840 |
| YTD | 1.47 | 0.52 | - | -54.5 | 39 | 4,203 | 407,702 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 0.58 | 0.59 | 0.74 | 1.13 | 1.29 | 0.03 | 0.91 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -43.41 | 70.1 | -21.70 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 42.01 | NA | 44.54 |
| R&D | 14.61 | NA | 34.36 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 300.0 | 300.0 | 16.7 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.10 | 0.10 | -0.30 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 54.89 |
| Current Ratio | 2.5 |
| Quick Ratio (Acid Test) | 2.4 |
| Liquidity Ratio (Cash) | 2.41 |
| Receivables Turnover | 1.1 |
| Average Collection Period | 327 |
| Working Capital/Equity | -26.0 |
| Working Capital pS | 0.19 |
| Cash-Flow pS | -0.75 |
| Free Cash-Flow pS | -0.68 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -8.64 |
| Financial Leverage Ratio (Assets/Equity) | 0.0 |
| Debt Ratio | 311.5 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | -129.7 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.13 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 8.88 |
| Tobin's Q Ratio | 1.73 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -1.77 |
| Enterprise Value (EV)/Free Cash Flow | -0.42 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -0.72 |
| Price/Book Ratio - LTM | 0.00 |
| Price/Cash Flow Ratio | -0.7 |
| Price/Free Cash Flow Ratio - LTM | -0.9 |
| Price/Sales Ratio | 969.94 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.13 |
| Tangible Book Value pS - LTM | -0.80 |
| Book Value pS - LTM | 0.00 |
| Capital Invested pS | -0.70 |
| Cash pS - LTM | 0.20 |
| Cash Flow pS - LTM | -0.86 |
| Free Cash Flow pS - LTM | -0.66 |
| Earnings pS (EPS) | -0.81 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -141,990.48 |
| Free Cash Flow Margin 5YEAR AVG | -62,450.21 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | -0.00 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | -0.00 |
| Return on Capital Invested (ROCI) | 91.8 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 735.5 |
| Assets Productivity | 0.00 |
| Return on Assets (ROA) | -194.2 |
| Return on Assets (ROA) - 5YEAR AVRG. | -50.8 |
| Gross Profit Margin | 77.8 |
| Gross Profit Margin - 5YEAR AVRG. | 71.9 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 480 |
| Revenue per Employee | 273 |
| Net Income per Employee | -382,779 |
| Average Collection Period | 480 |
| Receivables Turnover | 1.1 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 13,538.10 |
| Assets/Revenue | 0.00 |
| Net Working Capital Turnover | 0.00 |
| Fixed Assets Turnover | 0.02 |
| Total Assets Turnover | 0.0 |
| Revenue per $ Cash | 0.00 |
| Revenue per $ Plant | 0.02 |
| Revenue per $ Common Equity | 0.00 |
| Revenue per $ Capital Invested | 0.00 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 36904.8 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 5131.4 |
| Research & Devlopment (R&D) as % of Revenue | 123928.6 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 123928.6 |
|
|  
|
| |
 |  |
